Related Experiment Video

Updated: Sep 26, 2026

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model
08:22

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model

Published on: October 27, 2020

Warm and tepid cardioplegia: do they provide equal myocardial protection?

Pierre-Emmanuel Falcoz1, Djamel Kaili, Sidney Chocron

  • 1Department of Thoracic and Cardiovascular Surgery, Hôpital Jean-Minjoz, Besançon, France. pierre-emmanuel.falcoz@wanadoo.fr

The Annals of Thoracic Surgery
|March 20, 2003
PubMed

Insights

This study found no significant difference in myocardial protection between warm and tepid cardioplegia during coronary artery bypass graft surgery, based on cardiac troponin I release. Both methods appear equally effective for patient outcomes.

Area of Science:

  • Cardiovascular Surgery
  • Cardiology
  • Biomarkers

Background:

  • Cardiac troponin I (CTnI) is a validated biomarker for myocardial injury.
  • Evaluating myocardial protection during cardiac surgery is critical.
  • Coronary artery bypass graft (CABG) surgery requires effective myocardial preservation strategies.

Purpose of the Study:

  • To compare the efficacy of intermittent antegrade warm cardioplegia versus tepid blood cardioplegia.
  • To assess myocardial protection using cardiac troponin I (CTnI) release as the primary endpoint.
  • To evaluate clinical and biological data for differences in myocardial protection.

Main Methods:

  • Prospective, randomized study involving 70 patients undergoing first elective CABG.
  • Patients were assigned to either warm or tepid cardioplegia groups.
  • Serial CTnI concentrations were measured pre-cardiopulmonary bypass and at 6, 9, 12, and 24 hours post-reperfusion.

Main Results:

  • No statistically significant difference in total CTnI release between warm (8.23 ± 20.5 μg) and tepid (3.19 ± 2.4 μg) cardioplegia groups (p=0.23).
  • Adjusted CTnI concentrations did not differ between groups (p=0.06).
  • Perioperative myocardial infarction occurred in 4 patients in the warm group versus none in the tepid group (p=0.12).

Conclusions:

  • This study demonstrates no discernible advantage of warm over tepid cardioplegia for myocardial protection in CABG.
  • Both clinical and biological data suggest comparable efficacy between the two cardioplegia strategies.
  • Further research may explore specific patient subgroups or alternative myocardial protection techniques.
Abstract

More Related Videos

Murine Isolated Heart Model of Myocardial Stunning Associated with Cardioplegic Arrest08:30

Murine Isolated Heart Model of Myocardial Stunning Associated with Cardioplegic Arrest

Published on: August 6, 2015

Pre-clinical Model of Cardiac Donation after Circulatory Death06:26

Pre-clinical Model of Cardiac Donation after Circulatory Death

Published on: August 2, 2019

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Decreased Body Temperature01:29

Decreased Body Temperature

A decreased body temperature can occur in patients with hypothermia and frostbite. Heat loss with extended cold exposure overpowers the body's ability to create heat, resulting in hypothermia. Core temperature readings help classify hypothermia. Mild hypothermia is temperatures between 32 °C (89.6 °F) and 35°C (95 °F) and is caused by impaired thermoregulation. Moderate hypothermia is temperatures between 28 C (82.4 °F) and 32 °C (89.6 °F) caused by sustained extreme cold exposure, and severe...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...